Searchable abstracts of presentations at key conferences in endocrinology

ea0003p25 | Clinical Case Reports | BES2002

Congenital adrenal hyperplasia: A tale of two enzymes

Chaudhri O , Goodlad C , Hameed A , Barakat M , Meeran K

A 24-year old male who, was normal at birth, became listless and volume depleted at 3 weeks of age. Investigations yielded an Addisonian picture (serum Na+ 115 mmol/l; K+ 8.2 mmol/l; urea 15.8 mmol/l). Serum 17-hydroxyprogesterone (17-OHP) levels were measured and found to be high (2,564 nmol/l). Urinary 17-oxosteroids and 17-OHP were also elevated. The neonate was thought to have 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH) and therapy with fludrocortisone an...

ea0003p26 | Clinical Case Reports | BES2002

A new management for congenital adrenal hyperplasia?

Goodlad C , Chaudhri O , Barakat M , Meeran K

A thirty year old woman with complete 21-hydroxylase deficiency presented with a five centimetre adrenal mass necessitating operative removal to exclude malignant change. Her medical management had always been unsatisfactory, and she had been tried on both hydrocortisone and dexamethasone. When taking 1 milligram dexamethasone daily she had partially suppressed androgen levels, (evidenced by a fall in 17-hydroxy-progesterone levels to 29 nmol/l), at the expense of marked Cushi...

ea0003p63 | Clinical Case Reports | BES2002

A case of false immunoassay results due to assay interference

Park A , Goodlad C , Chaudhri O , Donaldson M , Ghatei M , Meeran K

WF a 52 year old female was referred to the Hammersmith Hospital in August 2001 for further investigation of her persistently elevated fasted gut hormones (GIH) [all previously assayed at the Hammersmith Hospital]. WF was initially diagnosed with irritable bowel syndrome 16 years ago. Following an exacerbation of her condition 9 years ago, fasting gut hormones were performed, which showed gross elevation of all peptides measured.The possibility of a neuroendocrine tumour was p...

ea0003p126 | Endocrine Tumours and Neoplasia | BES2002

Treatment options for refractory hypercalcaemia in a patient with PTHrP-secreting neuroendocrine tumour and primary hyperparathyroidism

Barakat M , Hameed A , Goodlad C , Tait P , Meeran K , Howard J , Williams G

A 47 year-old woman was referred with hypercalcaemia. She was receiving lithium, haloperidol and olanzapine for a schizo-affective disorder. Five years previously she had been diagnosed with liver metastases and a biopsy confirmed a neuroendocrine tumour. She had been told that her life-expectancy was limited, and she was discharged. Her calcium was 2.7mmol/l three years ago. At presentation to her local hospital, her calcium was >6.0mmol/l. She was treated aggressively wi...